Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viral vector-mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome.

The Journal of clinical investigation - 15 Jun 2023

Fadila Saja, Beucher Bertrand, Dopeso-Reyes Iria González, Mavashov Anat, Brusel Marina, Anderson Karen, Ismeurt Caroline, Goldberg Ethan M, Ricobaraza Ana, Hernandez-Alcoceba Ruben, Kremer Eric J, Rubinstein Moran

Abstract excerpt

Dravet syndrome (DS), an intractable childhood epileptic encephalopathy with a high fatality rate, is typically caused by loss-of-function mutations in one allele of SCN1A, which encodes NaV1.1, a 250-kDa voltage-gated sodium channel. In contrast to other epilepsies, pharmaceutical treatment for DS is limited. Here, we demonstrate that viral vector-mediated delivery of a codon-modified SCN1A open reading frame...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epilepsies, Myoclonic
Share to Epilepsy research and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hippocampus

Share to Mutation

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to Neuroscience and Neuropharmacology Research

Share to Seizures

Source

Open in PubMed Open full text

Identifiers

PMID: 37192002
DOI: 10.1172/JCI159316
PMCID: PMC10266792

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viral vector-mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome.PMID 37192002Read ↗

Exogenous Na <sub>V</sub> 1.1 activity in excitatory and inhibitory neurons reverts Dravet syndrome comorbidities when delivered post-symptom onset in mice with DravetSemantic proximity Read ↗

Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome miceSemantic proximity Read ↗

SCN1A as a therapeutic target for Dravet syndrome.Semantic proximity Read ↗

Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestationsSemantic proximity Read ↗

Cell-Selective Adeno-Associated Virus-Mediated SCN1A Gene Regulation Therapy Rescues Mortality and Seizure Phenotypes in a Dravet Syndrome Mouse Model and Is Well Tolerated in Nonhuman Primates.Semantic proximity Read ↗

A novel rat model of Dravet syndrome recapitulates clinical hallmarksSemantic proximity Read ↗

AAV delivery of RNA editing machinery rescues SUDEP and seizure phenotype in a mouse model of Dravet SyndromeSemantic proximity Read ↗

Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutationSemantic proximity Read ↗

Interneuron-specific dual-AAV SCN1A gene replacement corrects epileptic phenotypes in mouse models of Dravet syndrome.Semantic proximity Read ↗

Genetic therapeutic advancements for Dravet Syndrome.Semantic proximity Read ↗

AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet SyndromeSemantic proximity Read ↗

Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.